查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566979

兽用疫苗佐剂市场：按类型、给药途径、动物类型分类：2024-2033年全球机会分析与产业预测

Veterinary Vaccine Adjuvants Market By Type , By Route of Administration By Type of Animal : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

动物疫苗佐剂市场

2023年兽用疫苗佐剂市值为4亿美元，预计2024年至2033年复合年增长率为4.6%，到2033年将达6亿美元。

兽用疫苗佐剂是增强动物疫苗免疫反应的重要成分。佐剂是为了增强疫苗产生的免疫反应而添加的生物活性化合物。佐剂作用机转包括透过增强呈现抗原过程或刺激特定受体来调节免疫途径。兽用疫苗中最常见的佐剂形式是油乳剂、铝盐、脂质体、细菌衍生物和皂素。

宠物饲养趋势的增加和动物健康支出的激增是动物疫苗佐剂市场的关键驱动因素。此外，过去几年动物疾病爆发迅速增加，推动了对兽用疫苗佐剂的需求。最近的趋势包括在疫苗中添加基于奈米颗粒的佐剂。基于奈米颗粒的佐剂可以控制释放并封装抗原，从而防止降解。此外，基于微粒的佐剂和基因佐剂因其高度标靶化的作用机製而受到广泛欢迎。

然而，一些佐剂可能会引起动物严重的全身反应或局部反应原性，引发安全性问题并阻碍市场开拓。此外，疫苗开发的进步正在消除对佐剂的需求，而不会限制疫苗的效力。预计此类技术创新将限制未来几年的市场开拓。儘管疫苗配方方面有了技术创新，但在产生有效免疫反应方面仍存在一些差距，包括病原体多样性和疫苗株毒力回应。这些缺点为参与企业兽用疫苗佐剂市场提供了有利的机会。此外，政府的各种动物疫苗接种倡议，例如印度畜牧和酪农部的口蹄疫疫苗接种计划，正在为市场扩张开闢新的途径。

按部门审查

兽用疫苗佐剂市场按类型、给药途径、动物类型和地区细分。依类型分为明矾&钙盐、油乳佐剂、脂质体&古体、奈米颗粒&微粒子等。依给药途径分为口服、皮下、肌肉注射等。依动物种类分为家畜动物和伴同性动物。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，明矾和钙盐细分市场将在 2023 年占据主导地位。

依给药途径，2023年肌肉注射细分市场占较高市场占有率。

依动物类型划分，2023 年畜牧业占较高份额。

按地区划分，北美地区 2023 年收益最高。

可以使用此报告进行客製化（需要额外费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章兽用疫苗佐剂市场：依类型

  • 市场概况
  • 明矾钙盐
  • 油乳化助剂
  • 脂质体和古体
  • 奈米颗粒和微米颗粒
  • 其他的

第五章兽用疫苗佐剂市场：依给药途径

  • 市场概况
  • 口服
  • 皮下给药
  • 肌肉注射
  • 其他的

第六章动物疫苗佐剂市场：依动物类型

  • 市场概况
  • 家畜动物
  • 伴同性动物

第七章兽用疫苗佐剂市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国兽用疫苗佐剂市场
    • 加拿大兽用疫苗佐剂市场
    • 墨西哥兽用疫苗佐剂市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国兽用疫苗佐剂市场
    • 法国兽用疫苗佐剂市场
    • 英国兽用疫苗佐剂市场
    • 义大利兽用疫苗佐剂市场
    • 西班牙兽用疫苗佐剂市场
    • 其他欧洲兽用疫苗佐剂市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本兽用疫苗佐剂市场
    • 中国兽用疫苗佐剂市场
    • 澳洲兽用疫苗佐剂市场
    • 印度兽用疫苗佐剂市场
    • 韩国兽用疫苗佐剂市场
    • 其他亚太兽用疫苗佐剂市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西动物疫苗佐剂市场
    • 沙乌地阿拉伯动物疫苗佐剂市场
    • 南非兽用疫苗佐剂市场
    • 其他拉丁美洲/中东/非洲动物疫苗佐剂市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • SEPPIC
  • SPI Pharma, Inc.
  • Bioveta AS
  • Croda Internation PLC
  • Merck And Co., Inc.
  • MVP Laboratories
  • OZ Biosciences
  • InvivoGen Corporation.
  • Evonik Industries AG
  • Zoetis, Inc.
简介目录
Product Code: A324537

Veterinary Vaccine Adjuvants Market

The veterinary vaccine adjuvants market was valued at $0.4 billion in 2023 and is projected to reach $0.6 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.

A veterinary vaccine adjuvant is an element essential to enhance the immune response of the administered vaccine in animals. An adjuvant is a bioactive compound that upon addition elevates the immune response generated by vaccines. The mechanism of action of adjuvants involves enhancement in the antigen presentation process or modulation of immune pathways through the stimulation of certain receptors. The most common forms of adjuvants included in veterinary vaccines are oil emulsions, aluminum salts, liposomes, bacterial derivatives, and saponins.

Increase in the trend of petkeeping and surge in expenditure on their health are the key drivers of the veterinary vaccine adjuvants market. Moreover, the prevalence of diseases in animals has upsurged over the past few years, thereby boosting the demand for veterinary vaccine adjuvants. In recent times, the addition of nanoparticle-based adjuvants in vaccines is trending in the market as they offer controlled release and encapsulate the antigens, thus preventing their degradation. Furthermore, microparticle-based and genetic adjuvants are acquiring prominent traction owing to their highly targeted action mechanism.

However, several adjuvants potentially cause severe systemic reactions and local reactogenicity in animals, raising concerns pertaining to their safety and hampering the development of the market. In addition, advancements in vaccine development are eliminating the requirement of adjuvants, without limiting the efficacy of vaccines. Such innovations are anticipated to restrain the development of the market in upcoming years. Despite the innovations in vaccine formation, several gaps exist in the generation of effective immune response, such as pathogen variability and virulent reversion of vaccine strains. These shortcomings present lucrative opportunities for the players in the veterinary vaccine adjuvant market. Further, the implementation of different veterinary vaccination drives by governments, such as the foot and mouth disease vaccination program by the Department of Animal Husbandry & Dairying in India, open new avenues for market expansion.

Segment Review

The veterinary vaccine adjuvants market is segmented into type, route of administration, type of animal, and region. On the basis of type, the market is divided into alum & calcium salts, oil emulsion adjuvants, liposomes & archaeosomes, nanoparticles & microparticles, and others. By route of administration, it is classified into oral, subcutaneous, intramuscular, and others. As per type of animal, it is bifurcated into livestock animals and companion animals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the alum & calcium salts segment dominated the market in 2023.

By route of administration, the intramuscular segment accounted for a high market share in 2023.

As per type of animal, the livestock animals segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global veterinary vaccine adjuvants market include SEPPIC, SPI Pharma, Inc., Bioveta AS, Croda Internation PLC, Merck & Co., Inc., MVP Laboratories, OZ Biosciences, InvivoGen Corporation., Evonik Industries AG, and Zoetis, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Alum and Calcium Salts
  • Oil Emulsion Adjuvants
  • Liposomes and Archaeosomes
  • Nanoparticles and Microparticles
  • Others

By Route Of Administration

  • Oral
  • Subcutaneous
  • Intramuscular
  • Others

By Type Of Animal

  • Livestock Animals
  • Companion Animals

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • SEPPIC
    • SPI Pharma, Inc.
    • Bioveta AS
    • Croda Internation PLC
    • Merck & Co., Inc.
    • MVP Laboratories
    • OZ Biosciences
    • InvivoGen Corporation.
    • Evonik Industries AG
    • Zoetis, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Alum And Calcium Salts
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Oil Emulsion Adjuvants
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Liposomes And Archaeosomes
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Nanoparticles And Microparticles
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Route of Administration
  • 5.2. Oral
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Subcutaneous
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Intramuscular
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Others
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Type of Animal
  • 6.2. Livestock Animals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Companion Animals
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: VETERINARY VACCINE ADJUVANTS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Route of Administration
    • 7.2.4. Market Size and Forecast, By Type of Animal
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Veterinary Vaccine Adjuvants Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Route of Administration
      • 7.2.6.3. Market Size and Forecast, By Type of Animal
    • 7.2.7. Canada Veterinary Vaccine Adjuvants Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Route of Administration
      • 7.2.7.3. Market Size and Forecast, By Type of Animal
    • 7.2.8. Mexico Veterinary Vaccine Adjuvants Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Route of Administration
      • 7.2.8.3. Market Size and Forecast, By Type of Animal
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Route of Administration
    • 7.3.4. Market Size and Forecast, By Type of Animal
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Veterinary Vaccine Adjuvants Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Route of Administration
      • 7.3.6.3. Market Size and Forecast, By Type of Animal
    • 7.3.7. France Veterinary Vaccine Adjuvants Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Route of Administration
      • 7.3.7.3. Market Size and Forecast, By Type of Animal
    • 7.3.8. UK Veterinary Vaccine Adjuvants Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Route of Administration
      • 7.3.8.3. Market Size and Forecast, By Type of Animal
    • 7.3.9. Italy Veterinary Vaccine Adjuvants Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Route of Administration
      • 7.3.9.3. Market Size and Forecast, By Type of Animal
    • 7.3.10. Spain Veterinary Vaccine Adjuvants Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Route of Administration
      • 7.3.10.3. Market Size and Forecast, By Type of Animal
    • 7.3.11. Rest of Europe Veterinary Vaccine Adjuvants Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Route of Administration
      • 7.3.11.3. Market Size and Forecast, By Type of Animal
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Route of Administration
    • 7.4.4. Market Size and Forecast, By Type of Animal
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Veterinary Vaccine Adjuvants Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Route of Administration
      • 7.4.6.3. Market Size and Forecast, By Type of Animal
    • 7.4.7. China Veterinary Vaccine Adjuvants Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Route of Administration
      • 7.4.7.3. Market Size and Forecast, By Type of Animal
    • 7.4.8. Australia Veterinary Vaccine Adjuvants Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Route of Administration
      • 7.4.8.3. Market Size and Forecast, By Type of Animal
    • 7.4.9. India Veterinary Vaccine Adjuvants Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Route of Administration
      • 7.4.9.3. Market Size and Forecast, By Type of Animal
    • 7.4.10. South Korea Veterinary Vaccine Adjuvants Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Route of Administration
      • 7.4.10.3. Market Size and Forecast, By Type of Animal
    • 7.4.11. Rest of Asia-Pacific Veterinary Vaccine Adjuvants Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Route of Administration
      • 7.4.11.3. Market Size and Forecast, By Type of Animal
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Route of Administration
    • 7.5.4. Market Size and Forecast, By Type of Animal
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Veterinary Vaccine Adjuvants Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Route of Administration
      • 7.5.6.3. Market Size and Forecast, By Type of Animal
    • 7.5.7. Saudi Arabia Veterinary Vaccine Adjuvants Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Route of Administration
      • 7.5.7.3. Market Size and Forecast, By Type of Animal
    • 7.5.8. South Africa Veterinary Vaccine Adjuvants Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Route of Administration
      • 7.5.8.3. Market Size and Forecast, By Type of Animal
    • 7.5.9. Rest of LAMEA Veterinary Vaccine Adjuvants Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Route of Administration
      • 7.5.9.3. Market Size and Forecast, By Type of Animal

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. SEPPIC
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. SPI Pharma, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Bioveta AS
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Croda Internation PLC
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Merck And Co., Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. MVP Laboratories
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. OZ Biosciences
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. InvivoGen Corporation.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Evonik Industries AG
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Zoetis, Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments